Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00247676 | An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer | completed | Phase 2 | 37 | PfizerINDUSTRY | 3 | Feb 18, 2010 | clinicaltrials |
| NCT00089648 | SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma | completed | Phase 2 | 61 | PfizerINDUSTRY | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00140478 |
| Mifepristone (RU-486) in Androgen Independent Prostate Cancer |
| completed |
| Phase 2 |
| 48 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Dec 9, 2009 |
| clinicaltrials |
| NCT00006361 | SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2009 | clinicaltrials |
| NCT00319969 | Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. | completed | Phase 2 | 76 | Celgene CorporationINDUSTRY | 1 | Sep 30, 2009 | clinicaltrials |
| NCT00280618 | Oxaliplatin in Unresectable Hepatocellular Carcinoma | completed | Phase 2 | — | SanofiINDUSTRY | 0 | Sep 15, 2009 | clinicaltrials |
| NCT00495846 | GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma(SS-HCC) | completed | Phase 2 / Phase 3 | 25 | Federico II UniversityOTHER | 1 | Aug 17, 2009 | clinicaltrials |
| NCT00953394 | 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors | completed | Phase 2 | 29 | University of Turin, ItalyOTHER | 1 | Aug 6, 2009 | clinicaltrials |
| NCT00464919 | Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 50 | National Taiwan University HospitalOTHER | 1 | Jul 7, 2009 | clinicaltrials |
| NCT00106002 | Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer | completed | Phase 2 | 37 | Eli Lilly and CompanyINDUSTRY | 1 | Jun 1, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00259987 | Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus | completed | Phase 2 | 24 | GlaxoSmithKlineINDUSTRY | 3 | May 18, 2009 | clinicaltrials |
| NCT00591188 | Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens | completed | Phase 2 | 49 | Kidney Cancer Research BureauOTHER | 1 | May 1, 2009 | clinicaltrials |
| NCT00102700 | ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer | completed | Phase 2 | 66 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 29, 2009 | clinicaltrials |
| NCT00165191 | Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00165230 | Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors | completed | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00358930 | A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 60 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Apr 28, 2009 | clinicaltrials |
| NCT00255476 | The IRESSA Novel Head and Neck Chemotherapy Evaluation Study | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00586040 | Photochemical Tissue Bonding(PTB) | completed | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Apr 10, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00609401 | Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)(ROSORC) | completed | Phase 2 | 90 | Italian Trial in Medical OncologyOTHER | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00619541 | Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)(P2) | completed | Phase 2 | 46 | Italian Trial in Medical OncologyOTHER | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00197444 | Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer | completed | Phase 2 | 33 | Hamamatsu UniversityOTHER | 1 | Feb 20, 2009 | clinicaltrials |
| NCT00043407 | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00116610 | Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer | completed | Phase 2 | 75 | Poniard PharmaceuticalsINDUSTRY | 3 | Jan 21, 2009 | clinicaltrials |
| NCT00496301 | Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC(SOGUG-02-06) | completed | Phase 2 | 40 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Jan 14, 2009 | clinicaltrials |
| NCT00290953 | Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide(SESAME) | completed | Phase 2 / Phase 3 | 432 | SanofiINDUSTRY | 14 | Dec 23, 2008 | clinicaltrials |
| NCT00444782 | A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma. | completed | Phase 2 | 41 | Pharmexa A/SINDUSTRY | 3 | Dec 18, 2008 | clinicaltrials |
| NCT00377936 | EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas | completed | Phase 2 | 212 | MediGeneINDUSTRY | 3 | Nov 14, 2008 | clinicaltrials |
| NCT00770393 | Laryngeal Preservation in Pyriform Sinus Carcinoma | completed | Phase 2 / Phase 3 | 71 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Oct 10, 2008 | clinicaltrials |
| NCT00425204 | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | completed | Phase 2 | 31 | AmgenINDUSTRY | 0 | Sep 15, 2008 | clinicaltrials |
| NCT00129844 | Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer | completed | Phase 2 | 108 | Pharmacyclics LLC.INDUSTRY | 2 | Aug 20, 2008 | clinicaltrials |
| NCT00056693 | Treatment With SU11248 in Patients With Neuroendocrine Tumors | completed | Phase 2 | 107 | PfizerINDUSTRY | 1 | Jul 21, 2008 | clinicaltrials |
| NCT00422786 | Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma | completed | Phase 2 | 10 | Thallion PharmaceuticalsINDUSTRY | 1 | Jul 15, 2008 | clinicaltrials |
| NCT00697814 | Clomiphene in Males With Prolactinomas and Persistent Hypogonadism | completed | Phase 2 | 15 | Federal University of São PauloOTHER | 1 | Jun 16, 2008 | clinicaltrials |
| NCT00298688 | A Study of IRESSA in Relapsed and Refractory Small Cell Lung Cancer | completed | Phase 2 | 56 | AstraZenecaINDUSTRY | 2 | Jun 12, 2008 | clinicaltrials |
| NCT00139243 | Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 4, 2008 | clinicaltrials |
| NCT00139269 | Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 38 | Dana-Farber Cancer InstituteOTHER | 0 | Jun 4, 2008 | clinicaltrials |
| NCT00139230 | Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 3, 2008 | clinicaltrials |
| NCT00095186 | Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma | completed | Phase 2 | 40 | AgennixINDUSTRY | 1 | Apr 10, 2008 | clinicaltrials |
| NCT00635323 | Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma | completed | Phase 2 | 73 | PfizerINDUSTRY | 4 | Apr 7, 2008 | clinicaltrials |
| NCT00059735 | A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma | completed | Phase 2 | 30 | Eisai Inc.INDUSTRY | 2 | Mar 5, 2008 | clinicaltrials |
| NCT00001339 | A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00082082 | A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma | completed | Phase 2 | — | SciClone PharmaceuticalsINDUSTRY | 1 | Jan 15, 2008 | clinicaltrials |
| NCT00056173 | Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Aptose Biosciences Inc.INDUSTRY | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00165217 | Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00388063 | Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 2 | 55 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00464295 | Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)(HCC-CAP) | completed | Phase 2 | 15 | Aga Khan UniversityOTHER | 1 | Dec 14, 2007 | clinicaltrials |
| NCT00122876 | Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 25 | Light Sciences OncologyINDUSTRY | 3 | Dec 7, 2007 | clinicaltrials |
| NCT00073112 | A Study of ABT-751 in Patients With Renal Cell Cancer | completed | Phase 2 | 60 | AbbottINDUSTRY | 2 | Nov 29, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Feb 18, 2010source: clinicaltrials